Simon Amy sold $429K of BEAM

Simon Amy (Chief Medical Officer) sold 16,667 shares of Beam Therapeutics Inc. (BEAM) at $25.74 ($0.43M total) on 2026-07-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Simon Amy
Published Jul 29, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 29, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BEAM
Neutral
high confidence
Mentioned
$BEAM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BEAMNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale size, price, and 10b5-1 status; it does not include any new clinical, regulatory, or financial guidance.

02

Market read

Traders may note insider selling, but the 10b5-1 framing suggests limited incremental information for valuation.

03

What to watch

The article provides only the sale details, not any concurrent buy activity, changes in guidance, or operational updates that would connect the transaction to fundamentals.

Relevance 3/10Novelty 3/10Timing: Filed on 2026-07-29, covering a sale executed on 2026-07-27.

Background

This is an SEC Form 4 insider transaction for Beam Therapeutics, reported by the Chief Medical Officer.

Company-level read

Ticker impact

$BEAMNeutralHigh confidence
Context

Beam Therapeutics CMO Simon Amy filed a Form 4 showing an open-market sale of 16,667 shares at $25.7417 on 2026-07-27.

Expected impact

Likely minimal immediate price impact; any effect is more about sentiment than new company information.

Evidence & confidence

The disclosure is a Form 4 insider transaction, but it explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification or tax planning and may not reflect negative expectations, especially under a 10b5-1 plan.

Key entities

  • Beam Therapeutics Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Simon Amy

    Chief Medical Officer who sold shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BEAMHighAI 9/10

Beam Sickle Cell Therapy Meets Pivotal Goals

Beam Therapeutics reported positive pivotal trial results for risto-cel, its sickle cell treatment, meeting all primary and secondary endpoints. The trial showed patients stayed free of severe vaso-occlusive crises for at least 12 months. Beam plans to file for FDA approval by year-end 2026, aiming to be the first base-editing therapy approved in the US. The company will present detailed results at a medical meeting in 2027.